Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Status: Enrolling
Updated:  12/31/1969
Wellmont Medical Associates Oncology and Hematology-Kingsport
mi
from
Kingsport, TN
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Status: Enrolling
Updated: 12/31/1969
Wellmont Medical Associates Oncology and Hematology-Kingsport
mi
from
Kingsport, TN
Click here to add this to my saved trials
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Status: Enrolling
Updated:  12/31/1969
Marshfield Clinic
mi
from
Marshfield, WI
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Status: Enrolling
Updated: 12/31/1969
Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Hospital
mi
from
Phoenix, AZ
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Improving Goals of Care Discussion in Advanced Cancer Patients
Improving Advanced Cancer Patient-Centered Care by Enabling Goals of Care Discussions
Status: Enrolling
Updated:  12/31/1969
Smilow Cancer Hospital, Yale Cancer Center, Yale University
mi
from
New Haven, CT
Improving Goals of Care Discussion in Advanced Cancer Patients
Improving Advanced Cancer Patient-Centered Care by Enabling Goals of Care Discussions
Status: Enrolling
Updated: 12/31/1969
Smilow Cancer Hospital, Yale Cancer Center, Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Improving Goals of Care Discussion in Advanced Cancer Patients
Improving Advanced Cancer Patient-Centered Care by Enabling Goals of Care Discussions
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Beth Israel
mi
from
New York, NY
Improving Goals of Care Discussion in Advanced Cancer Patients
Improving Advanced Cancer Patient-Centered Care by Enabling Goals of Care Discussions
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Beth Israel
mi
from
New York, NY
Click here to add this to my saved trials
Improving Goals of Care Discussion in Advanced Cancer Patients
Improving Advanced Cancer Patient-Centered Care by Enabling Goals of Care Discussions
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Improving Goals of Care Discussion in Advanced Cancer Patients
Improving Advanced Cancer Patient-Centered Care by Enabling Goals of Care Discussions
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Improving Goals of Care Discussion in Advanced Cancer Patients
Improving Advanced Cancer Patient-Centered Care by Enabling Goals of Care Discussions
Status: Enrolling
Updated:  12/31/1969
Kings County Hospital Center
mi
from
New York, NY
Improving Goals of Care Discussion in Advanced Cancer Patients
Improving Advanced Cancer Patient-Centered Care by Enabling Goals of Care Discussions
Status: Enrolling
Updated: 12/31/1969
Kings County Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention
Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal mHealth Intervention
Status: Enrolling
Updated:  12/31/1969
Partners HealthCare Connected Health
mi
from
Boston, MA
Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention
Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal mHealth Intervention
Status: Enrolling
Updated: 12/31/1969
Partners HealthCare Connected Health
mi
from
Boston, MA
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated:  12/31/1969
UCLA Hematology/Oncology Clinic
mi
from
Los Angeles, CA
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated: 12/31/1969
UCLA Hematology/Oncology Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated:  12/31/1969
Providence Portland Medical Center
mi
from
Portland, OR
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated: 12/31/1969
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated:  12/31/1969
Yale University
mi
from
New Haven, CT
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated:  12/31/1969
University of Chicago
mi
from
Chicago, IL
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated: 12/31/1969
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated:  12/31/1969
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated: 12/31/1969
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine St. Louis
mi
from
Saint Louis, MO
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated:  12/31/1969
Center for Oncology and Blood Disorders
mi
from
Houston, TX
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated: 12/31/1969
Center for Oncology and Blood Disorders
mi
from
Houston, TX
Click here to add this to my saved trials
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin
mi
from
Madison, WI
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2'- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers
Status: Enrolling
Updated:  12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2'- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers
Status: Enrolling
Updated: 12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
A Multi-Center, Single Arm, Phase II Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer: HCRN GI14-186
Status: Enrolling
Updated:  12/31/1969
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
A Multi-Center, Single Arm, Phase II Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer: HCRN GI14-186
Status: Enrolling
Updated: 12/31/1969
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
A Multi-Center, Single Arm, Phase II Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer: HCRN GI14-186
Status: Enrolling
Updated:  12/31/1969
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
A Multi-Center, Single Arm, Phase II Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer: HCRN GI14-186
Status: Enrolling
Updated: 12/31/1969
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
A Multi-Center, Single Arm, Phase II Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer: HCRN GI14-186
Status: Enrolling
Updated:  12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
A Multi-Center, Single Arm, Phase II Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer: HCRN GI14-186
Status: Enrolling
Updated: 12/31/1969
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
Regorafenib in Metastatic Colorectal Cancer: An Exploratory Biomarker Study
Status: Enrolling
Updated:  12/31/1969
Georgetown University
mi
from
Washington,
A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
Regorafenib in Metastatic Colorectal Cancer: An Exploratory Biomarker Study
Status: Enrolling
Updated: 12/31/1969
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Johns Hopkins
mi
from
Baltimore, MD
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute Univ. of Utah HCI
mi
from
Salt Lake City, UT
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute Univ. of Utah HCI
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Toronto,
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Toronto,
Click here to add this to my saved trials
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis
mi
from
Portland, OR
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Nashville, TN
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
Status: Enrolling
Updated:  12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
Status: Enrolling
Updated: 12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Thomas C Lenzmeier, M.D., P.C
mi
from
Glendale, AZ
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Thomas C Lenzmeier, M.D., P.C
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Central Arizona Medical Associates, PC
mi
from
Mesa, AZ
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Central Arizona Medical Associates, PC
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Fiel Family and Sports Medicine
mi
from
Tempe, AZ
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Fiel Family and Sports Medicine
mi
from
Tempe, AZ
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Cassidy Medical Group/Radiant Research, Inc.
mi
from
Carlsbad, CA
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Cassidy Medical Group/Radiant Research, Inc.
mi
from
Carlsbad, CA
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Kindred Medical Institute For Clinical Trials, LLC
mi
from
Corona, CA
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Kindred Medical Institute For Clinical Trials, LLC
mi
from
Corona, CA
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
UCLA, Division of Digestive Diseases
mi
from
Los Angeles, CA
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
UCLA, Division of Digestive Diseases
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
John D. Homan, MD
mi
from
Newport Beach, CA
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
John D. Homan, MD
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Diverse Research Solutions
mi
from
Oxnard, CA
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Diverse Research Solutions
mi
from
Oxnard, CA
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Ventura County Gastroenterology
mi
from
Oxnard, CA
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Ventura County Gastroenterology
mi
from
Oxnard, CA
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Desert Oasis Healthcare Medical Group
mi
from
Palm Springs, CA
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Desert Oasis Healthcare Medical Group
mi
from
Palm Springs, CA
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Advanced Pain Diagnostics & Solutions
mi
from
Sacramento, CA
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Advanced Pain Diagnostics & Solutions
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Innovative Research of West Florida, Inc.
mi
from
Clearwater, FL
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Innovative Research of West Florida, Inc.
mi
from
Clearwater, FL
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Homestead Medical Research
mi
from
Homestead, FL
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Homestead Medical Research
mi
from
Homestead, FL
Click here to add this to my saved trials
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated:  12/31/1969
Health Awareness
mi
from
Jupiter, FL
A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval
Status: Enrolling
Updated: 12/31/1969
Health Awareness
mi
from
Jupiter, FL
Click here to add this to my saved trials